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Abstract. Stromal derived factors, SDFs, are a loosely defined
group of molecules that may be generated by stromal cells.
Two of the stromal derived factors, SDF-1 and SDF-4 belong
to the chemokine family. Other SDFs, such as SDF-2 and
SDF-5 are not well defined and their biological functions are
less known. Although SDF-1 and its receptor have been
strongly indicated in the progression of various cancers
including breast cancer, little is known with regard to the role
of other SDFs in malignant conditions including breast
cancer. In the present study, we analysed the pattern of
expression of SDF-2, SDF2-like-1, SDF-4 and SDF-5 in
breast cancer tissues and cells, at transcript and protein levels.
It was found that SDF-2, SDF2-L1, SDF-4, and SDF-5 were
ubiquitously expressed in various cancer cell lines. However,
in clear contrast to SDF-1 whose over-expression has been
shown to be linked to a poor clinical outcome, the present
study provides evidence that the opposite appear to be true
for SDF-2/SDF2-L1, SDF-4 and SDF-5. Significantly low
levels of SDF-2 and SDF-4 were seen in patients with poor
clinical outcome (with metastatic disease and death as a
result of breast cancer, p<0.05, and p<0.01 respectively),
when compared with patients who remained disease-free.
SDF2-L1 and SDF-5 showed a similar trend. SDF-2 and
SDF-L1 were also independent prognostic indicators (p=0.047
and p=0.012, respectively). It is concluded that SDF-2,
SDF-4 and SDF-5 are expressed in mammary tissues and
cells and that a reduced level of SDF-2, SDF2-L1 and SDF-4
are associated with a poor clinical outcome. These SDFs thus
have prognostic value and warrant further investigation in
their biological functions and clinical value.
Introduction
Stromal cell derived factors refer to a group of proteins that
are derived from stromal cells, including fibroblasts. The
best described of such factors is SDF-1/CXCL12 (CXC
motif, ligand 12), which is a known chemotactic cytokine.
SDF-1 is also a member of CXC subfamily of chemokines,
which are expressed in several tissues and organs, including
skin, lymph nodes, lung, liver, and bone marrow, and mainly
produced by stromal cells such as fibroblasts and bone
marrow endothelial cells (1-3). SDF-1, via its receptor
CXCR4, plays an important role in physiological and
pathological conditions including cancer (4-7). We have
recently demonstrated that SDF-1 was over-expressed in
human breast cancer and the level of SDF-1 was significantly
correlated with the metastasis and overall survival in human
breast cancer (8-10).
However, other stromal derived factors, are less well
defined. In the last decade, SDF-2, SDF-3, SDF-4, and SDF-5
have been identified. Except SDF-3 which has only been
described in murine samples, SDF-2 (11), SDF-4 (12) and
SDF-5 (13) have been reported in humans. In addition, a
variant of SDF-2 has also been reported, and so named
SDF2-like-1 protein (14). SDF-4, also known as Cab45, is a
Ca2+-binding protein localised in the Golgi lumen (12,15-17).
SDF-2 was initially identified from mouse stromal cell
line ST2 (11), which is a 211-amino acid protein that
includes a 30-amino acid hydrophobic signal peptide.
Because the protein lacks a hydrophobic region in addition
to that at the N terminus. It has been suggested that the
protein is likely to be a secretory and not a membrane
protein. A human homologue of murine SDF-2 was also
identified from a glioblastoma cell line, a protein that is
92.4% identical to that of the mouse (11). SDF-4, also
known as Cab45, is a 45-kDa protein identified from mouse
3T3-L1 adipocytes (15). It is a Ca2+-binding protein localised
in the Golgi lumen (15-17). SDF4/Cab45 is ubiquitously
expressed and binds Ca2+ due to the presence of six EF-hand
motifs. Within the superfamily of calcium-binding proteins,
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it belongs to a recently identified group of proteins consisting
of reticulocalbin.
Little is known about these new SDFs in cancer. In
colorectal cancer, SDF-2 was reported to be under-expressed in
cancer and that the reduction of SDF-2 may be linked to a
poor survival (18). SDF-4 has been shown to be an over-
expressed protein and a potential new biomarker in pan-
creatic cancer cell lines (17). There has been no study on the
expression of SDF-2, SDF-4, SDF-5 in breast cancer. In the
present study, we evaluated the expression of SDF-2/-4/-5
and SDF2-like molecules in a panel of cancer cell lines and a
cohort of breast tumours, whose SDF-1 expression pattern
was previously reported (8). A further aim of the study was
to deduce a possible correlation between SDFs and clinical
outcome and compare the pattern of expression with SDF-1. 
Materials and methods
Materials. Monocloncal anti-human SDF-2 (SC100660), goat
anti-human SDF-4 (SC-47373) and goat anti-human SDF-1
(SC-6193) antibodies and a universal staining kit were from
Santa Cruz Biotechnology Ltd. (Santa Cruz, CA, USA), and
Vector Laboratories (Nottingham, UK), respectively. Human
breast cancer cell lines, MDA-MB-231, MDA-MB-436,
MCF-7, ZR-75-1, BT474, BT482, BT549, human fibroblast
cell line MRC5, were obtain from ATCC (MD, USA) and
ECACC (Salisbury, UK) respectively. Human endothelial
cell line HECV was from from Interlab Cell line Collection
(ICLC, Naples, Italy). RNA extraction kit and the first strand
RT synthesis kits were obtained from AbGene Ltd. (Surrey,
UK). PCR primers were designed using Beacon Designer
(Palo Alto, CA, USA) and synthesised by Invitrogen Ltd.
(Pasley, Scotland, UK). Primer sequences are given in Table I.
Molecular biology grade agarose and DNA ladder were from
Invitrogen. Master mix for routine PCR and quantitative PCR
was from AbGene. 
Mammary tissue samples. Tumour tissues (n=120) and
normal background tissues (n=32) of the breast were
collected immediately after surgery and stored frozen until
use. Patients were routinely followed clinically after surgery.
The presence of tumour cells in the collected tissues was
verified by a consultant pathologist, who examined H&E
stained frozen sections. Patients were routinely followed-up
on a regular basis and details stored in a database. The
median follow-up period was 120 months.
Tissue processing, RNA extraction and cDNA synthesis. Frozen
sections of tissues were cut at a thickness of 5-10-μm using a
cryostat and were kept for immunohistochemistry and routine
histology. A further 15-20 sections were mixed and homo-
genised using a hand-held homogeniser, in ice cold RNA
extraction solution. The concentration of RNA was determined
using a UV spectrophotometer. Reverse transcription was
carried using an RT kit with an anchored oligo-dt primer
supplied by AbGene, using 1 μg total RNA in a 96-well
plate. The quality of cDNA was verified using ß-actin
primers. The transcript of interest, including SDF-2, SDF2-
L1, SDF-4, SDF-5 and GAPDH (house-keeping control),
were amplified using conventional PCR and separated on a
2% agarose gel, before stained and documented with a
UviTech gel Imager (UviTech, Cambridge, UK).
Quantitative analysis of the SDF-2, SDF2-L1, SDF-4 and
SDF-5 transcripts. The level of the SDF transcripts from the
above-prepared cDNA was determined using a real-time
quantitative PCR, based on the Amplifluor™ technology,
modified from a method previously reported (19,20). Briefly,
pairs of PCR primers were designed using the Beacon Designer
software (version 2, CA, USA), but to one of the primers, an
additional sequence, known as the Z sequence (5'-actgaacctg
accgtaca'-3) which is complementary to the universal Z
probe (Intergen Inc., Oxford, UK), was added. The transcript
levels of GAPDH, used as a house-keeping control was
also quantified and used for normalisation purpose. Primer
sequences are given in Table I. The reaction was carried
out using the following: Hot-start Q-master mix (AbGene),
10 pmol of specific forward primer, 1 pmol reverse primer
which has the Z sequence, 10 pmol of FAM-tagged probe
(Intergen Inc.), and cDNA from approximate 50 ng RNA.
The reaction was carried out using IcyclerIQ™ (Bio-Rad)
which is equipped with an optic unit that allows real-time
detection of 96 reactions, using the following condition: 94˚C
for 12 min, 50 cycles of 94˚C for 15 sec, 55˚C for 40 sec and
72˚C for 20 sec. The levels of the transcripts were generated
from a standard that was simultaneously amplified with the
samples.
Immunohistochemical analysis of SDF proteins. This was
based on the method we previously described (21). Frozen
sections of mammary tissues were cut at a thickness of 6-μm
using a cryostat. The sections were mounted on super frost
plus microscope slides, air dried and then fixed in a mixture
of 50% acetone and 50% methanol. The sections were then
placed in ‘Optimax’ wash buffer for 5-10 min to rehydrate.
Sections were incubated for 20 min in a horse serum blocking
solution and probed with the primary antibody (1:100 dilution)
for 1 h at room temperature. Following extensive washings,
sections were incubated for 30 min in the secondary biotiny-
lated antibody (Multilink Swine anti-goat/mouse/rabbit
immunoglobulin, Dako Inc.). Following washings, Avidin
Biotin Complex (Vector Laboratories) was then applied to the
sections followed by extensive washings. Diaminobenzidine
chromogen (Vector Labs) was then added to the sections
which were incubated in the dark for 5 min. Sections were
then counter stained in Gill's Haematoxylin and dehydrated
in ascending grades of methanol before clearing in xylene
and mounting under a cover slip. 
Statistical analysis was carried out using Mann-Whitney
U test and the Kruskal-Wallis test. Correlation was carried
out using Spearman's rank test on SigmaPlot (version 11). 
Results
Distribution of SDF-2 and SDF-4 in mammary tissues. Normal
mammary tissues displayed a good level of SDF-2, in both
epithelial cells and in particular in stromal cells in the gland
(Fig. 1A). The staining of SDF-2 protein tends to be cyto-
plasmic. In contrast, in breast cancer tissues, there was a
marked reduction in the staining in both tumour cells and
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stromal cells. Cancer cells were frequently seen lacking
staining (Fig. 1A3/A4). 
The staining of SDF-4 in mammary tissues tends to be
weak, compared with that of SDF-2 staining. In normal
tissues, the SDF-4 staining appears to be more prominent in
epithelial cells than in stromal cells (Fig. 1B1/B2). There is
decreased staining in both cancer cells and stromal cells
(Fig. 1B3/B4). 
The pattern of staining of both SDF-2 and SDF-4 are thus
in clear contrast to that of SDF-1, which showed a markedly
increased staining in cancer cells compared to normal
epithelial cells (Fig. 1C) and as we previously reported (8).
Expression of SDF transcripts in human breast cancer cell
lines. Fig. 2 shows the pattern of expressions of SDF-2,
SDF2-like-1, SDF-4 and SDF-5 in a panel of breast cancer
cell lines, a fibroblast cell line and an endothelial cell line. It
is evident that the transcript expression of the SDFs are
rather ubiquitous, with most cells having detectable SDF-2,
SDF-2L, SDF-4 and SDF-5 transcripts. 
SDF-2 and SDF2-like-1 transcripts show reduced expression
in tumours from patients with aggressive disease. The most
significant observation with the SDF-2 transcript levels was
their correlation with the clinical outcome (Fig. 3A). They
were significantly lower in patients who developed
metastatic disease (0.0014±0.0001) and patients who died of
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Table I. Primer sequences.
––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– 
Molecule Sense primer (5'-3') Anti-sense primer (5'-3')
––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– 
SDF-2 ggtgaagctactcaatacgc actgaacctgaccgtacagtaactgttgctgtcatcca
SDF2-like-1 cttacgggcaagaacctg actgaacctgaccgtacagcactgtccataggtcca
SDF-4 aagctgatggtcatcttttc actgaacctgaccgtacacgtcttctccatgatcca
SDF-5 tttttatttttgcaggcttc actgaacctgaccgtacagacaacgacctttgcatc
SDF-1 ttcaggagtacctggagaaa actgaacctgaccgtacacctaacactggtttcagagc
GAPDH (for Q-PCR) aaggtcatccatgacaactt actgaacctgaccgtacagccatccacagtcttctg
GAPDH (for conventional RT-PCR) ggctgcttttaactctggta gactgtggtcatgagtcctt
––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– 
Figure 1. Immunohistochemical staining of SDF-2 (A1-A4), SDF-4 (B1-B4)
and SDF-1 (C1 and C2) in normal and tumour tissues. SDF-2 stained
strongly in mammary epithelial cells (A1/A2 black arrows), but weakly in
breast cancer cells (A3/A4 black arrows). Stromal cells (white arrows)
showed similar pattern of staining. Similarly, SDF-4 staining, although
weak, are also seen in mammary epithelial cells (B1/B2), but virtually absent
in cancer cells (B3/B4). The pattern of staining of both SDF2 and SDF-4 are
in contrast to SDF-1 staining (C1 and C2) in which cancer cells show a
stronger staining (C2 black arrows) than epithelial cells (C1 black arrow).
Figure 2. Detection of SDF transcripts in human cell lines. MCF-7 (1),
ZR-75-1 (2), MDAMB-436 (3), MDA-MB-231 (4), BT474 (5), BT482 (6),
and BT549 (7) are human breast cancer lines, MRC5 (8) and HECV (9)
human fibroblast cell line and endothelial cell line, respectively. (+) positive
control is cDNA from human mammary tissues.
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Figure 3. Levels of SDF-2 (A), SDF2-L1 (B), SDF-4 (C) and SDF-5 (D) transcripts in correlation with clinical outcome.
Figure 4. Levels of SDF-2 (A), SDF2-L1 (B), SDF-4 (C) and SDF-5 (D) transcripts in correlation with the Nottingham prognostic index (good - index, <3.4;
moderate, 3.4-5.4; poor, >5.4).
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breast cancer-related disease (0.049±0.037) compared with
the patients who are disease-free (9.4±4.8), p<0.05 and p=0.05,
respectively. Using the Nottingham Prognostic Index as the
prognostic factor, no consistent pattern was observed, except
that patients with poor predicted prognosis had low levels of
the transcript (Fig. 4A). There was otherwise no significant
correlation with tumour grade (Fig. 5A).
Similarly, tumours from poor predicted prognosis showed
dramatic low levels of the SDF2-L1 transcript compared with
NPI-1 tumours (0.012±0.008 in poor prognosis vs. 0.529±0.50
in good prognosis group) (Fig. 4B). Furthermore, grade-3
tumours also displayed low levels of SDF2-L1 compared to
grade-1 and grade-2 tumours (0.13±0.1 vs. 1.7±1.4 and
2.06±2.0) (Fig. 5B). Perhaps the most striking observation
for SDF2 L1 was that tumours from patients who developed
metastasis (0.0001±0.000014) and from those who died of
breast cancer during the follow-up period (0.061±0.051) had
markedly lower levels compared with tumours from patients
who remained disease-free (1.54±1.20) (Fig. 3B). Finally,
ER-positive tumours (0.15±0.12) had low levels of SDF2-L1
compared with ER-negative tumours (1.7±1.4). Multivariate
analysis revealed that SDF-2 is an independent prognostic
indicator for overall survival (p=0.047) and that SDF2-L1 is
an independent prognostic factor for disease-free survival
(p=0.012).
Expression of SDF-4 transcript. Patients who died of breast
cancer (7.9±7.6) and patients who developed metastasis
(0.01±0.01), had significantly lower levels of the SDF-4
transcripts compared with those who remained disease-free
(248±118), p<0.01 and p<0.05 vs. disease-free group, respec-
tively (Fig. 3C). No significant correlation was seen between
SDF-4 transcript and prognostic indices and tumour grade
(Figs. 4C and 5C). It is interesting to note that ER-positive
tumours had a significantly lower levels of SDF-4 (34±23)
than ER-negative tumours (328±143), p=0.045. 
SDF-5 transcripts are reduced in aggressive tumours. SDF-5
expression showed a similar pattern to that of SDF2-L1. It is
noteworthy that patients who were disease-free (2230±1290)
had markedly high levels of SDF5 transcript compared with
those with metastatic diseases (62.7±41.6) and those who
died of breast cancer (495±446) (Fig. 3D). No significant
correlation between SDF-5 and prognostic indices was seen,
despite the stepwise increase of the transcript with tumour
grade. The latter was nonetheless not statistically significant.
Finally, using Spearman's rank correlation analysis, we failed
to identify a significant correlation between these SDF-2,
SDF2-L1, SDF-4, SDF-5 and SDF-1. 
Discussion
In the present study, we report that the expression pattern of
SDF-2, SDF2-like-1, SDF-4 and SDF-5 are sharply different
from that of SDF-1, in human breast cancer. SDF-2, SDF2-L1
and SDF-4 showed an inverse correlation with the outcome
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Figure 5. Levels of SDF-2 (A), SDF2-L1 (B), SDF-4 (C) and SDF-5 (D) transcripts in correlation with tumour grade.
205-211.qxd  29/5/2009  01:41 ÌÌ  ™ÂÏ›‰·209
of the patients, in a sharp contrast to SDF-1, increased levels of
which has been reported to be linked to a poor prognosis (8).
The present study has two significant observations. First,
SDF-2/SDF2-like-1 and SDF-4 are potential prognostic
indicators for patients with breast cancer. Second, the contrast
in expression pattern of SDF-1 and other SDFs, namely,
SDF-2L1, SDF-2 and SDF-4. There have been some extensive
reports in the literature to show that SDF-1 is over-expressed
in breast cancer and that an over-expression of SDF-1 is
linked to aggressiveness of the disease. We have shown that
SDF-1 is linked to the long-term survival of the patients with
breast cancer (8,9). In the present study and using the same
cohort for which we investigated expression of SDF-1, we
now have first line evidence to show that other SDFs, SDF-2,
SDF2-L1, SDF-4, and SDF-5 have a complete different
expression from that of SDF-1, and that patients with
aggressive tumours have low levels of SDF-2, SDF2-L1 and
SDF-4, a striking pattern in comparison with SDF-1. 
SDFs are broadly defined and are largely referring to
those molecules secreted by stromal cells, with little correlation
to their function and structure. In all the SDFs, SDF-1 and
SDF-4 belong to the chemokine superfamily, whereas SDF-5
belongs to the secreted frizzled proteins. These genes are
coded in different products. Thus, the expression pattern of
these SDFs do not necessarily have a natural connection.
This is indeed reflected by the present study, in which
contrast in pattern of expression was seen between SDF-1
and SDF-2/4/5. SDF-5 was initially discovered from a cDNA
library and was to be similar to secreted frizzled-like protein-2
(SFRP-2) or secreted apoptosis-related protein 1 (SARP-1),
which forms part of the frizzled transmembrane protein
family (13). These proteins are receptors for Wnt family
members. The function of SDF-5 is not clear, although it has
been suggested that when over-expressed in breast cancer
cells it regulates apoptosis of the cells, possibly by way of ß-
catenin (22,23). Little is available with regard to the
expression of these new SDFs in cancer. The results on
SDF-2 in the present study is in line with another study (18),
which indicated that a reduction of SDF-2 in colorectal cancer
may be linked to a poor prognosis. Expression pattern between
SDF-2 and SDF2-L1 is similar to that in the present study,
which may suggest that the two variants likely share a similar
function(s) on breast cancer cells. This is interesting, as the
two variants were initially discovered from different cell types,
i.e., SDF-2 from murine stromal cells and SDF-2L1 from
murine hepatocellular carcinoma cells although they share
64% similarities in their amino acid sequences (11,14). SDF-
2L1 also share similarities with POMT1 and POMT2
(Protein O-Mannosyltransferase), molecules linked to the
Walker-Warburg syndrome (24).
The clear contrast of the expression between SDF-1, and
SDF-2/SDF2-L1/SDF-4/SDF-5, argues for a completely
different role of these factors in the development and
progression of breast cancer. The role of SDF-1 and its
specific receptor, CXCR4 in breast cancer is well
established. Both SDF-1 and its receptor are associated with
a poor clinical outcome. This is clearly supported by the well
understood function of the cytokine-receptor complex. As
already discussed, these ‘stromal’ derived factors have little
in common in their structure. 
It is clear from the immunohistochemical analysis of tissues
and PCR on cell lines that the 4 new SDFs are ubiquitously
expressed. This observation was made in the initial study
by Fukuda et al (14), on SDF2-L1. SDF-5 was initially shown
to be expressed at higher levels in muscle tissues (13). It
seems though that SDF-2, SDF-4 and SDF-5 share the same
pattern of expression in the scenario of breast cancer. 
In conclusion, the present study has shown for the first
time that SDF-2, SDF-4 and SDF-5, members of the stromal
derived factors, have a sharply different pattern of expression
from that of SDF-1. While SDF-1, as we previously reported,
showed over-expression in aggressive tumours and high
levels of SDF-1 is linked to a poor prognosis, SDF-2 and
SDF-4 showed a distinct pattern, in which low levels of
SDF-2 and SDF-4 are linked to a poor clinical outcome of
the patients. This study thus reveals that SDF-2/SDF-4 may
act in a different manner in comparison with SDF-1. This
warrants further investigation as to the potential therapeutic
role of SDF-2 and SDF-4 in breast cancer.
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